Fig. 1



WST assay
GCT case 1
GCT case 2
Cell viability
1.2
1
.8
.6
.4
.2
0
P=0.0167
p<0.001
p<0.001
p<0.001
p<0.001
p<0.001
p<0.001
Cont 5 10 50 100 200μM
Zaltoprofen

Fig. 2



TUNEL assay after induction of Zaltoprofen
Cont
100 μ M 8hr
200 μ M 8hr
100 μ M 24hr
200 μ M 24hr
TUNEL
DAPI
Merged

Fig. 3



Labeling Index of TUNEL positive cells
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0
＊＊
＊＊
＊
100μM 8hr
100μM 24hr
200μM 8hr
200μM 24hr
Zaltoprofen
＊＊ : p<0.01
＊ : p<0.05

Fig. 4



Caspase 3 assay after induction of Zaltoprofen
Cont
100 μM 8hr
200 μM 8hr
100 μM 24hr
200 μM 24hr
Caspase 3
DAPI
Merged

Fig. 5



＊＊
＊＊
＊＊
＊＊ ; p<0.01
Labeling Index of Caspase3 positive cells
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0
100 μM 8hr
100 μM 24hr
200 μM 8hr
200 μM 24hr
Zaltoprofen

Fig. 6



Expression of PPAR-γ after induction of zltoprofen
Cont
10 μM
50 μM
100 μM
200 μM
PPAR-γ
DAPI
Merged

Fig. 7



＊＊
＊＊
＊＊
＊
＊＊ : p<0.01
＊ : p<0.05
Labeling Index of PPARγ positive cells
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0
cont
10
50
100
200
Zaltoprofen （μM）

Fig. 8



Expression of HCS Lipid TOX after induction of zltoprofen
Cont
10 μM
50 μM
100 μM
HCS Lipid TOX
DAPI
Merged

Fig. 9



Labelling Index of HCS LipidTOX positive cells
1
.9
.8
.7
.6
.5
.4
.3
.2
.1
0
＊＊
＊＊
＊＊
cont
10
50
100
Zaltoprofen （μM）
＊＊：p<0.01

Fig. 10



Control
(without administration
of zaltoprofen)
Administration of
zaltoprofen
TUNEL
Caspase 3
TUNEL
Caspase 3
DAPI
DAPI
Merged
Merged

Fig. 11



Control
(without administraion
of zaltoprofen)
Administration of
zaltoprofen
PPARγ
PPARγ
DAPI
DAPI
Merged
Merged

Fig. 12



WST assay GCT case1
Acetoaminophen
Indometacin
Dicrofenac
Troglitazone
Cell viability
Cont 5 10 50 100 200μM
Cont 25 50 75 100μM
p<0.001
p<0.0193

Fig. 13



WST assay GCT case2
Acetoaminophen
Indometacin
Dicrofenac
Troglitazone
Cell viability
P=0.003
P<0.001
P<0.001
P=0.0194
p<0.001
p<0.001
p<0.001
P=0.001
P<0.001
Cont 5 10 50 100 200μM
Cont 25 50 75 100μM

Fig. 14



WST assay after siRNA (PPAR-γ) transfection GCT Case 1
si-PPAR-γ
si-negative control
Control
% of control (O.D. 450nm)
P=0.0004
P<0.0001
P<0.0001
0 200μM
Zaltoprofen
P=0.0065
P=0.0003
P<0.0001
0 60μM
Troglitazone

Fig. 15



WST assay after siRNA (PPAR-γ) transfection GCT case 2
si-PPAR-γ
si-negative control
Control
P=0.2233
P<0.0001
P<0.0001
% of control (O.D. 450nm)
0
200μM
Zaltoprofen
P=0.3749
P=0.0015
P<0.0001
60μM
Troglitazone

Fig. 16



WST assay
Nodular tenosynovitis
(GCT of tendon sheath)
PVNS (diffuse-type GCT)
Cell viability
**p<0.001
Cont
50
100
200
400
800μM
Zaltoprofen

Fig. 17



WST assay
Nodular tenosynovitis
(GCT of tendon sheath)
PVNS (diffuse-type GCT)
Cell viability
1.2
1
.8
.6
.4
.2
0
Cont 12.5 25 50 100 200μM
Troglitazone

Fig. 18



Nodular tenosynovitis (GCT of tendon sheath)
Control
Zaltoprofen
Troglitazone
TUNEL
DAPI
merged

Fig. 19



Labeling index of TUNEL positive cells
50
40
30
20
10
0
P=0.0021
0
400μM
Zaltoprofen
Labeling index of TUNEL positive cells
50
40
30
20
10
0
P<0.0001
0
200μM
Troglitazone

Fig. 20



PVNS (diffuse-type GCT)
Control
Zaltoprofen
Troglitazone
TUNEL
DAPI
merged

Fig. 21



Labeling index of TUNEL positive cells
50
40
30
20
10
0
P=0.0055
0
400μM
Zaltoprofen
Labeling index of TUNEL positive cells
50
40
30
20
10
0
P=0.0002
0
200μM
Troglitazone

Fig. 22



Nodular tenosynovitis (GCT of tendon sheath)
Control
Zaltoprofen
Troglitazone
Caspase 3
DAPI
merged

Fig. 23



Labeling index of caspase 3 positive cells
50
40
30
20
10
0
P=0.0244
0
400μM
Zaltoprofen
Labeling index of caspase 3 positive cells
50
40
30
20
10
0
P=0.0043
0
200μM
Troglitazone

Fig. 24



PVNS (diffuse-type GCT)
Control
Zaltoprofen
Troglitazone
Caspase 3
DAPI
merged

Fig. 25



Labeling index of caspase 3 positive cells
50
40
30
20
10
0
P=0.0001
0
400μM
Zaltoprofen
Labeling index of caspase 3 positive cells
50
40
30
20
10
0
P=0.0024
0
200μM
Troglitazone

Fig. 26



Nodular tenosynovitis (GCT of tendon sheath)
Control
Zaltoprofen
Troglitazone
PPARγ
DAPI
merged

Fig. 27



Labeling index of PPARγ positive cells
50
40
30
20
10
0
P=0.0001
0
400μM
Zaltoprofen
Labeling index of PPARγ positive cells
50
40
30
20
10
0
P=0.0124
0
200μM
Troglitazone

Fig. 28



PVNS (diffuse-type GCT)
Control
Zaltoprofen
Troglitazone
PPARγ
DAPI
merged

Fig. 29



Labeling index of PPARγ positive cells
50
40
30
20
10
0
P<0.0001
0
400μM
Zaltoprofen
Labeling index of PPARγ positive cells
50
40
30
20
10
0
P=0.0024
0
200μM
Troglitazone

Fig. 30



Nodular tenosynovitis
(GCT of tendon sheath)
PVNS
(diffuse-type GCT)
Control
Zaltoprofen
Control
Zaltoprofen
HCS Lipid TOX
HCS Lipid TOX
DAPI
DAPI
merged
merged

Fig. 31



Nodular tenosynovitis
(GCT of tendon sheath)
Labeling index of HCS Lipid TOX positive cells
50
40
30
20
10
0
P=0.0039
0
400μM
Zaltoprofen
PVNS (diffuse-type GCT)
Labeling index of HCS Lipid TOX positive cells
50
40
30
20
10
0
P=0.0054
0
400μM
Zaltoprofen

Fig. 32



GCT Case 1
Cell viability
1.2
1
.8
.6
.4
.2
0
*, P<0.01
**, P<0.05
Cont 5 10 50 100 200μM
GCT Case 2
Cell viability
1.2
1
.8
.6
.4
.2
0
*, P<0.01
Cont 5 10 50 100 200μM
GCT of tendon sheath
Cell viability
1.2
1
.8
.6
.4
.2
0
*, P<0.01
**, P<0.05
Cont 5 10 50 100 200μM
Diffuse type GCT
Cell viability
1.2
1
.8
.6
.4
.2
0
*, P<0.01
**, P<0.05
Cont 5 10 50 100 200μM

Fig. 33




Fig. 34



Fig. 35



H
2012/11/22
09:26:10
WATER:Gd+3D COR T1W IDEAL
Se:7
Im:41
R
L
Yes
GR
FA:20 TR:8.06
TE:3.576 TI:0
4.00 mm
L:1184 W:2356
512×512 倍率×1.00
F

Fig. 36


H
WATER IDEAL T1W Oo (+OE)
Se:7
Im:49
2013/01/24
09:12:19
R
L
Yes
GR
FA:20 TR:6.976
TE:2.972 TI:0
4.00 mm
L:667 W:1378
512×512 倍率×1.00
F

Fig. 37


H
2012/07/05
15:40:56
Gd+ T1 sag FS
Se:11
Im:10
A
P
Yes
SE
FA:90 TR:616.668
TE:8.124 TI:0
4.00 mm
L:1495 W:2946
512×512 倍率×1.00
F

Fig. 38



Fig. 39


H
2012/10/01
14:54:24
CE T1 FS SAG
Se:10
Im:9
A
P
Yes
SE
FA:90 TR:516.668
TE:5.744 TI0
4.00 mm
L:1301 W:2826
512×512 倍率×1.00
F

Fig. 40




Fig. 41



Fig. 42




Fig. 43



Fig. 44




Fig. 45



Troglitazone
Cell viability
1.2
1
.8
.6
.4
.2
0
*, P<0.01
**, P<0.05
Cont 2.5 5 25 50 100 μM
Pioglitazone
Cell viability
*, P<0.01
Cont 5 10 50 100 200 μM
Zaltoprofen
Cell viability
*, P<0.01
Cont 5 10 50 100 200 μM

Fig. 46



H-EMC-SS
Cont.
zaltoprofen
troglitazone
pioglitazone
Caspase3
DAPI
merged

Fig. 47



Labeling index of caspase 3 positive cells
50
40
30
20
10
0
P=0.0358
P=0.0023
P=0.0357
0
200μM
100μM
Zaltoprofen
Troglitazone
Pioglitazone

Fig. 48




H-EMC-SS
Cont.
zaltoprofen
troglitazone
pioglitazone
PPARγ
DAPI
merged

Fig. 49


Labeling index of PPARγ positive cells
100
80
60
40
20
0
P=0.0005
0
200μM
Zaltoprofen
P=0.0005
0
100μM
Troglitazone
P=0.0014
0
200μM
Pioglitazone